Evidence map›Paper›PMID 36761888›Full record

ArticleFrontiers in veterinary science2023

Zhiting Guo, Ling Wang, Shahbaz Ul Haq, Lu Wang, Wenzhu Guo, Yongjiang Luo, Nabeel Ijaz

Open access · goldAbstract read
In one paragraph

Article in Frontiers in veterinary science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Zhiting GuoKey Laboratory of New Animal Drug Project, Lanzhou, Gansu, China.
Ling WangKey Laboratory of New Animal Drug Project, Lanzhou, Gansu, China.
Shahbaz Ul HaqKey Laboratory of New Animal Drug Project, Lanzhou, Gansu, China.
Lu WangEngineering Research Center of Ministry of Education for the Development and Utilization of Southwest Characteristic Medicine Biological Resources, School of Pharmacy, Guizhou University, Guiyang, China.
Wenzhu GuoKey Laboratory of New Animal Drug Project, Lanzhou, Gansu, China.
Yongjiang LuoKey Laboratory of New Animal Drug Project, Lanzhou, Gansu, China.
Nabeel IjazDepartment of Clinical Sciences, Faculty of Veterinary Sciences, Bahauddin Zakariya University, Multan, Pakistan.
Guizhou University · CNBahauddin Zakariya University · PKLanzhou Institute of Husbandry and Pharmaceutical Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ginseng has been used in biomedicine to prevent and treat decreased physical and mental capacities. Total ginsenosides (TG) from ginseng root which have antitumor and immune-enhancing properties, are the principal active components of Methods: The chlorosulphonic acid-pyridine technique, used for the sulfation modification of TG to improve their biological activity, and the infrared spectroscopic characteristics of TG and SMTG-d3 were investigated, and the effects of SMTG-d3 on immunocytes and cytokines relevant to tumor treatment were assessed. The MTT assay was used to assess the effect of TG and SMTG-d3 on the cytotoxicity and T-lymphocytic proliferation against mouse splenocytes. The LDH method was employed to evaluate NK activity induced by TG or SMTG-d3. The production levels of splenocytes-secreted IL-2 and IFN-γ and peritoneal macrophages-secreted TNF-α were determined using mouse ELISA kits. Results and discussion: It showed that the ideal conditions for the sulfation modification of TG: the volume ratio of chlorosulfonic acid to pyridine lower than 1:2.5; controlled amount of chlorosulfonic acid; and a yield of 51.5% SMTG-d3 (2 h, < 45°C). SMTG-d3 showed two characteristic absorption peaks at 1,230 cm

Indexed as

antitumorcytotoxicityimmunological activitysulphation derivativetotal ginsenosides (TG)

Identifiers

PMID36761888
PMCPMC9907730
OpenAlexW4317989807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.